040-000-286 Remdesivir, CAS 1809249-37-3

SKU: 040-000-286 Category:
Get A Quote

  I would like to join the mailing list to receive updates from Stanford Chemicals.
*: e-mail address with your company's domain name is preferred. Otherwise, we may not be able to process your inquiry.

Synonyms GS5437
Key words COVID-19, against viruses
Related products Hydroxychloroquine sulfate, Losartan Potassium


Remdesivir Specifications

Product Name Remdesivir
CAS Registry Number 1809249-37-3
Molecular Formula C27H35N6O8P
Molecular Weight 602.585 g·mol−1
Purity >99.9 %
Package 1kg-25kg; 1 g, 20g
Solubility DMSO : ≥ 125 mg/mL (207.44 mM)
Shelf life 2 years
Functions Treatment of COVID-19 infection

Remdesivir Description

Remdesivir (development code GS-5734) is a novel antiviral drug in the class of nucleotide analogs. It is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.

Remdesivir is a nucleotide prodrug of an adenosine analog. It binds to the viral RNA-dependent RNA polymerase and inhibits viral replication by terminating RNA transcription prematurely.


Remdesivir Applications

Remdesivir is a potent antiviral agent. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h.


  1. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18.
  2. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.